This triple-blinded randomized placebo control trial aims to investigate the safety and efficacy of Nutri-PEITC jelly, a functional food, in head and neck cancer patients. The primary outcome measure includes adverse events, health-related quality of life, tumor response and progression-free survival. The secondary outcome includes serum p53 and cytochrome C levels and functional status.
Previously, Nutri-jelly, a novel edible nutritious gel for patients with chewing and swallowing difficulties, was shown to be effective in improving the quality of life of head and neck cancer patients. Recently, Nutri-PEITC jelly is recently developed by addition of Phenethyl Isothiocyanate (PEITC), a phytochemical compound with chemopreventive action in animal bearing oral cancer. It intends to be a functional food for cancer survivor. The dose of PEITC in Nutri-jelly was based on safe and effective dose determined in animal studies. Furthermore, Nutri-PEITC jelly was proven safe in healthy volunteers who daily consumes for a consecutive month with no serious adverse events. The purpose of this study is to determine safety and efficacy of Nutri-jelly with PEITC in head and neck cancer patients. independent variable: continuous Nutri -jelly with PEITC intake dependent variable (outcome): adverse effects, health-related quality of life score, tumor response, progression-free survival, serum p53 and cytochrome C levels and functional status
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Enrollment
96
Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
National cancer institute
Bangkok, Bangkok, Thailand
Chonburi Cancer Hospital
Chon Buri, Changwat Chon Buri, Thailand
Lopburi Cancer Hospital
Lopburi, Thailand
Maharat Nakhon Ratchasima Hospital
Nakhon Ratchasima, Thailand
Adverse events
Evaluation of adverse events by physical examination, blood tests, and interviewing the subjects
Time frame: 1 month and 3 months after receiving intervention
Changes in Health-related quality of life score compared to baseline
Evaluation of Health-related quality of life by using questionnaire FACT-HN
Time frame: Baseline, 1 month and 3 months after receiving intervention
Changes in Tumor response compared to baseline
Evaluation of tumor response following RECIST criteria at 1 month and 3 months
Time frame: Baseline, 1 month, 3 months after receiving intervention
Progression-free survival time
The length of time during the intervention that the participant lives with stable disease
Time frame: The time of the intervention until any signs or symptoms of progressive disease be recorded.
Serum p53 level
Level of both wild type and mutant p53 in serum
Time frame: 1 month and 3 months after receiving intervention
Serum cytochrome C level
Level of cytochrome C in serum
Time frame: 1 month and 3 months after receiving intervention
Changes in Functional status
Evaluation of functional status using KPS (Karnofsky Performance Score) score
Time frame: Baseline, 1 month and 3 months after receiving intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Maha Vajiralongkorn Thanyaburi Hospital
Pathum Thani, Thailand